Abstract:Abstract Glioblastoma (GB) is one of the most frequent primary brain tumors in adults with an extremely poor prognosis and a very high demand for novel therapies. Poor prognosis has been linked to its complex biology, tumor heterogeneity and an increased activation of signaling pathways through various growth factor receptors signaling pathway. In particular, aberrant expression and activation of epidermal growth factor receptor (EGFR) expression has been found to be common in patients with GBM. However, no EGFR inhibitor has yet been approved for the treatment of patients with brain tumor and there is currently no comprehensive study of all members of the HER family in the progression brain tumors. The aim of this study was to investigate the role of all members of the HER family (EGFR, HER2 HER3 and HER4), other growth factor receptors (e.g., C-MET) and downstream cell signaling pathways in the growth of a panel of human brain cancer cell lines (HBCCLs) and response to therapeutic interventions. Using Sulforhodamine B colorimetric assay, the growth response of four HBCCLs to treatment with 18 agents targeting different members of the HER family and other growth receptors (e.g. C-met/ALK 7, PDGFRs, FGFRs, C-kit), cyclin dependent kinases inhibitors (e.g. CDKs 1/2/5/9, CDK4/6) and downstream signaling molecules (e.g. STAT3, Src, Abl) was examined. We determined the expression level of all members of the HER family in brain cancer cells by flow cytometry and Western blot and the effect of these agents on migration of brain cancer cells were determined using Incucyte. Of the targeted agents examined, the CDK 1/2/5/9 inhibitor dinaciclib was the most potent and inhibited growth for all four HBCCLs with an IC50 below 10nM. Of the HER inhibitors, neratinib and afatinib were more effective than erlotinib and lapatinib and inhibiting the growth of all HBCCLs at IC50 values below 700nM and 1.9 μM, respectively. Treatment with Src/Abl/c-kit inhibitor dasatinib, STAT3 inhibitor static, Abl/PDGFRα/VEGFR2/FGFR1 inhibitor Ponatinib and the TRK/ROS/ALK inhibitor entrecitinb also inhibited the growth of HBCCLs with IC50 value ranging from 0.06 - 2.96 μM, 1 - 3.8μM, 0.19- 0.42 μM and 2.85- 3.47μM, respectively. Interestingly, these agents were more effective in inhibiting growth of HBCCLs when proliferating at a slower rate. In addition to inhibiting the proliferation of HBCCLs, treatment with neratinib, dinaciclib, dasatanib, static and trametinib inhibited the migration of brain tumor cells. Finally, treatment with neratinib in combination with Palbociclib, AZD4547, trametinib and miransertib inhibited the growth of HBCCLs synergistically. Taken together, our results support further investigation on the therapeutic potential of irreversible pan HER in combination with the CDK inhibitor dinaciclib and other targeted agents in brain cancer. Citation Format: Ermira Mulliqi, Said A. Khelwatty, Anna L. Morgan, Keyoumars Ashkan, Helmout Modjtahedi. Growth response and migration of brain cancer cell lines to treatment with agents targeting different members of the HER family, CDKs and other signalling pathways. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6133.

Abstract 516: The role of clathrin-mediated endocytosis of EGFR in glioblastoma cell viability and cell cycle progression

Abstract LB304: Mechanisms of cell death escape in glioblastoma

Abstract 1125: Elucidating the transcriptomic response to EGFR-targeted therapy in EGFR-driven glioblastoma

Abstract 5444: EGFR missense mutation(s) induce OLIG2 expression to regulate glioma stem cells maintenance and therapeutic resistance

Abstract 6133: Growth response and migration of brain cancer cell lines to treatment with agents targeting different members of the HER family, CDKs and other signalling pathways

Abstract 3070: CDK12 is a novel therapeutic target in glioblastoma

Abstract 356: Pre-clinical investigations utilizing Bcl2 inhibitors in glioblastoma

Abstract 3003: Exon skipping for the tumor suppressor Annexin A7 promotes EGFR signaling in stem-like brain tumor initiating cells through receptor recycling

Abstract 3774: The effect of CDK5 on mitochondrial function in Glioblastoma Multiforme (GBM)

Abstract 3875: Glioblastoma mutational profiles drive cancer cell signaling and immune evasion

Abstract 1666: Novel Glucose Transporter Inhibitors Decrease Glioblastoma Growth and Glucose Uptake

Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors

Abstract 427: A molecular signature for the G6PC3/SLC37A2/SLC37A4 interactors in glioblastoma disease progression and in the acquisition of a brain cancer stem cell phenotype

Abstract 2917: Purifying cancer-associated fibroblasts (CAFs) from glioblastoma and defining their role in therapeutic resistance

Abstract 5443: Identifying key regulators of glioblastoma cancer stem cells

Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM

Abstract 3478: A multi-orthogonal strategy for targeting EGFRvIII expressing glioblastomas

Abstract 7204: Therapeutic potential of targeting autophagy to overcome chemoresistance in glioblastoma

Abstract 60: Functional mapping of glioblastoma recurrence reveals targetable dependencies in an axonal guidance pathway in highly invasive brain cancers

Abstract A043: Pericytes orchestrate a tumor-suppressive microenvironment by impinging on the crosstalk between macrophages and tumor-initiating cells in glioblastoma multiforme

Abstract 5841: A genome wide CRISPR-Cas9 screen identifies mediators of resistance to dual PI3K/mTOR inhibition in glioblastoma multiforme